Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on
Target Price
The average target price of CVAC is 5.5 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell